

AlzPED: A New Data Resource for Improving the Rigor, Reproducibility, Transparency and Translation of Alzheimer's Disease Preclinical Research

Shreaya Chakroborty¹, Lorenzo Refolo¹, Zane Martin¹, Ali Sharma¹, Katerina Mancevska, Cindy Sheffield², and Suzana Petanceska¹ ¹National Institute on Aging, USA, ²US Food and Drug Administration, USA

BACKGROUND


A major challenge to the successful development of therapies for Alzheimer's disease (AD) is the poor translation of preclinical efficacy from animal models to the clinic. Key contributing factors to the unsuccessful translation of therapeutic efficacy include:

- the failure of animal models to fully recapitulate human AD,
- poor rigor in study design, methodology and data analysis,
- failure to match outcome measures used in preclinical animal studies and clinical studies,
- poor reproducibility of published data, and
- publication bias in favor of reporting positive findings and under reporting negative findings.

To address key factors contributing to poor translation of preclinical efficacy from animal models to the clinic in AD therapy development, several advisory meetings and workshops including the National Institutes of Health (NIH) AD Summits in 2012 and 2015 were held. In response to expert recommendations from these meetings, the National Institute on Aging (NIA) and the NIH Library have created an open science knowledge portal – the Alzheimer's Disease Preclinical Efficacy Database or AlzPED. Through the following capabilities, AlzPED is intended to guide the development and implementation of strategies and recommendations for standardized best practices for the rigorous preclinical testing of AD candidate therapeutics:








CAPABILITIES AND SCOPE

AlzPED has the following capabilities:


- Provides researchers and information scientists with a facile way to survey existing AD preclinical therapy development literature and raise awareness about the elements of rigorous study design and requirements for transparent reporting.
- Currently hosts curated summaries from **917** preclinical efficacy studies published between 1996 and 2019.
- Influences the development and implementation of reproducibility strategies including guidelines for standardized best practices for the rigorous preclinical testing of AD candidate therapeutics.
- Provides search capability across relevant translational criteria data sets and external databases:
- Therapy Type (14 therapy types)
 Related Publications (PubMed)
- Therapeutic Agent (804 agents)
 Therapeutic Agents (PubChem and DrugBank)
- Therapeutic Target (167 targets)
 - Therapeutic Targets (Open Targets and Pharos)
- Animal Model (174 models) Principal Investigator
- Animal Model (Alzforum) Related Clinical Trials (ClinicalTrials.gov)
- Funding Source
- Related Patents (Google Patents and USTPO)
- Provides funding agencies with a tool for enforcement of requirements for transparent reporting and rigorous study design.
- Provides a platform for creating <u>citable reports/preprints</u> of <u>unpublished</u> studies, including studies with negative data.
- · Reports on the rigor of each study by summarizing the elements of experimental design.

ANALYTICS

KEY ELEMENTS OF RIGOROUS EXPERIMENTAL DESIGN





There is considerable variation in the frequency of reporting the 24 recommended elements of experimental design that improve the reproducibility and translational value of preclinical efficacy research. Data are presented as percentages calculated from 917 published preclinical efficacy studies published between 1996 and 2019 and curated in AlzPED.



LEFT: 9 **CORE** elements of experimental design that are **critical** for scientific rigor and reproducibility are poorly reported in preclinical research. RIGHT: Few studies report more than 5 core design elements, most reporting only 2-4 core design elements.


THERAPEUTICS: AGENTS AND TARGETS






LEFT: 804 therapeutic agents are catalogued in 14 categories. RIGHT: 167 therapeutic targets are catalogued in 8 categories. Data are presented as percentages calculated from 917 published preclinical efficacy studies published between 1996 and 2019 and curated in AlzPED.

OUTCOME MEASURES: FUNCTIONAL AND DESCRIPTIVE







Each curated study provides a snapshot of the measures tested and outcomes achieved in response to the therapeutic agent tested. AlzPED defines 21 different outcome measures that are categorized as LEFT: Functional or RIGHT: Descriptive. More than 1500 AD-related outcome measures are catalogued in AlzPED. Data are presented as percentages calculated from 917 published preclinical efficacy studies published between 1996 and 2019 and curated in AlzPED.

A CURATED RECORD IN AIZPED

EXAMPLE OF RIGOROUS STUDY DESIGN



UNPUBLISHED STUDY SUBMISSION PORTAL



Overview of the submission process for unpublished studies including negative data. Accepted studies are published in the AMP-AD Knowledge Portal. The Digital Object Identifier (DOI) provided is citable in grant applications and peer-reviewed publications.

SUMMARY

In summary:

- Analysis of curated studies in AlzPED, demonstrates serious deficiencies in reporting critical elements of methodology such as power calculation, blinding for treatment/outcomes, randomization, sex of animal used and balancing for sex, animal genetic background and others.
- These deficiencies in study design and methodology diminish the scientific rigor, reproducibility and translational value of the preclinical studies.
- It is evident that a standardized set of best practices is required for successful translation of therapeutic efficacy in AD research.